Mechanistically, treatment with IL-23mAB/PSMA-CAR significantly enhanced CD45RO+CD8+ and CD127+CD4+ CAR T cells and indicated a potential role for IL-23 in the efficacy of CAR T cell therapy against prostate cancer [108,109]. Here, IL23A is linked to prostate carcinoma.